Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab Long-Term Dose Trial in Multiple Sclerosis (RIDOSE-MS)
2018-000721-31Phase 2Active
- Sponsor
- Karolinska Institutet
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of rituximab in multiple sclerosis (MS), sponsored by Karolinska Institutet. Started Apr 2018; status: active.
02
Drugs
rituximab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2018-000721-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000721-31.